Pharmafile Logo

Serlopitant

- PMLiVE

Ipsen’s Bylvay approved by FDA for severe itching due to Alagille syndrome

As many as 88% of patients living with the condition experience severe pruritus

- PMLiVE

Menlo slumps as itching drug fails mid-stage trial

Shares in US biotech closed down almost a third after announcement

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links